Continuation and maintenance treatment trials of adjunctive imipramine therapy in patients with postpsychotic depression.
Four of five patients who had had an operationally defined syndrome of postpsychotic depression, which had been responsive to adjunctive imipramine added to an ongoing regimen of fluphenazine decanoate and benztropine, suffered a return of depressive symptomatology following the tapering of the adjunctive imipramine 6 months after the initial response to imipramine therapy. Four comparison patients who were not tapered experienced no such reexacerbations (p = .04). The authors discuss implications of this finding for maintenance adjunctive antidepressant treatment strategies.
Siris
S G
SG
Mount Sinai School of Medicine, City University of New York, N.Y.
Strahan
A
A
D001590:Benztropine / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005476:Fluphenazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000009:adverse effects* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D001590:Benztropine; C011825:fluphenazine depot; D007099:Imipramine; D005476:Fluphenazine